1. Redefining cerebral palsies as a diverse group of neurodevelopmental disorders with genetic aetiology.
- Author
-
van Eyk, Clare L., Fahey, Michael C., and Gecz, Jozef
- Subjects
- *
GENETIC disorders , *CEREBRAL palsy , *EPILEPSY , *ETIOLOGY of diseases , *PEOPLE with cerebral palsy , *LANGUAGE disorders - Abstract
Cerebral palsy is a clinical descriptor covering a diverse group of permanent, non-degenerative disorders of motor function. Around one-third of cases have now been shown to have an underlying genetic aetiology, with the genetic landscape overlapping with those of neurodevelopmental disorders including intellectual disability, epilepsy, speech and language disorders and autism. Here we review the current state of genomic testing in cerebral palsy, highlighting the benefits for personalized medicine and the imperative to consider aetiology during clinical diagnosis. With earlier clinical diagnosis now possible, we emphasize the opportunity for comprehensive and early genomic testing as a crucial component of the routine diagnostic work-up in people with cerebral palsy. The diagnosis of cerebral palsy is currently made on clinical observations only and does not consider aetiology or pathology. Here, van Eyk and colleagues review the current state of genomic testing in cerebral palsy and highlight the benefits of a 'genotype-first' approach for this group of disorders. Key points: Currently, a clinical diagnosis of cerebral palsy (CP) is made on observation of signs and symptoms and does not consider aetiology or pathology. CP encompasses a clinically heterogeneous group of disorders — together referred to as cerebral palsies — with at least one-third of cases having a genetic aetiology. CP has a high degree of genetic overlap with neurodevelopmental disorders, such as intellectual disability, epilepsy and autism, and should itself be considered, at least partly, a genetic neurodevelopmental disorder. The presence of known cerebral palsy risk factors, such as prematurity and growth restriction, and the absence of other comorbid neurodevelopmental phenotypes, including intellectual disability and epilepsy, do not rule out a genetic aetiology. Diagnostic practice has not evolved with the fast-accumulating evidence for a genetic contribution to CP aetiology; the nomenclature for genetic cases and the circumstances under which a genetic diagnosis should negate the CP clinical diagnosis lack consensus. An aetiology-driven diagnosis of CP involving a 'genotype-first' approach will bring tangible benefits to individuals with CP through precision medicine and improved clinical management. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF